CLOUDBREAK THERAPEUTICS LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2015-09-01
- Employees
- 11
- Market Cap
- -
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT05456425
- Locations
- 🇺🇸
The Eye Care Institute, Louisville, Kentucky, United States
🇦🇺The Centre for Eye Research Australia, East Melbourne, Melbourne, Australia
🇦🇺Eyeclinic Albury Wodonga, Albury, New South Wales, Australia
Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop
Phase 1
Completed
- Conditions
- Myopia, Progressive
- Interventions
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT05372991
- Locations
- 🇦🇺
USC, Brisbane, Australia
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 95
- Registration Number
- NCT05261386
- Locations
- 🇺🇸
David Research Wirta, Newport Beach, California, United States
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 92
- Registration Number
- NCT04884243
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT04884256
- Locations
- 🇺🇸
Global Research Management, Glendale, California, United States
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Phase 2
Completed
- Conditions
- Pterygium
- Interventions
- Drug: CBT-001 single doseDrug: VehicleDrug: CBT-001 Multi-dose
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Cloudbreak Therapeutics, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT03049852
- Locations
- 🇺🇸
Harvard Eye Associates, Laguna Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath